Expanded Access Remdesivir (RDV; GS-5734™)

Inclusion Criteria

• •DoD-affiliated personnel as defined in DoDI 6200.02, which includes emergency-essential civilian employees and/or contractor personnel accompanying the Armed Forces who are subject to the same health risk as military personnel
• •Have a laboratory-confirmed COVID-19 diagnosis with moderate to severe disease presentation as determined by the principal investigator
• •Patient or legally authorized representative (LAR) provides written informed consent, except as noted in 21 CFR 50.23
• •Understands and agrees to comply with planned study procedures
• •Available for clinical follow-up for duration of the treatment and follow-up period
• •Woman of childbearing potential must
• •* Have a negative pregnancy test within 24 hours before starting treatment
• •* Agree not to become pregnant during treatment and for 1 months after receiving remdesivir (Treatment will be a maximum of 10 doses given over a 10-day interval)
• •* Use at least 2 reliable forms of effective contraception, including 1 barrier method, during treatment and for 1 month after the treatment period